Navigation Links
Global Imaging Agents Industry
Date:7/3/2012

NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Imaging Agents Industry http://www.reportlinker.com/p0326398/Global-Imaging-Agents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_I

This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following Product Segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Daiichi Sankyo Company Limited, Eisai Co., Ltd, EUSA Pharma, Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3A. Contrast Media I-3X-Ray Contrast Media I-3Magnetic Resonance Imaging (MRI) Contrast Media I-4Ultrasound Contrast Media I-4B. Diagnostic Radiopharmaceuticals I-4II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

Industry Outlook II-1

Medical Imaging Industry Under the Impact of Economic Downturn II-2

Targeted Imaging - A Game Changer in the Making? II-2

Developing Countries to Spur Growth II-3

A Quick Primer On Imaging Agents II-3

Growth Drivers II-4

Growth Inhibitors II-5

Changing Dynamics of Imaging Agents II-6

Imaging Agents: Significant Growth Ahead II-7

Rise of Non-Ionizing Imaging Techniques II-7

Fusion Imaging Modalities: Greater Clinical Benefits II-8

Radioactive Isotopes Utilized in PET & SPECT Imaging Procedures II-8

Radiopharmaceuticals-An Exotic Tool II-9

Nanomaterials Taking the Center Stage II-9

Gadolinium Coated Nanoparticles- A Promising Imaging Agent II-9

A Peek Into Pricing Dynamics II-10

A Synoptic Overview II-10

Pros & Cons II-11

Positive Factors Driving Prices II-11

Negative Factors Bearing Down on Prices II-11

Reimbursements II-11

"Under the Umbrella" II-11

Europe II-12

United States II-12

2. MARKET TRENDS & ISSUES II-13Falling Prices Turn On the Heat II-13X-Ray Contrast Media: Declining Sector II-13MRI Contrast Media: Playing at Center Court II-13Impact Wielded by Ballooning MRI Practices II-13Ultrasound Contrast Media: A Rising Star in the Quadrant II-14Fledging Market Battles Teething Challenges II-15PET: A Prime Growth Driver for Radiopharmaceuticals II-15Nuclear Medicine: A Potential Growth Avenue forRadiopharmaceuticals II-16Select Cardiology and Oncology Radiopharmaceuticals II-16

3. COMPETITION II-17

Market Structure II-17

Big Guns in the Emerging MRI Market II-18

Bayer Schering Pharma AG: A Pioneering Developer of MRI

Contrast Agents II-18

Competitive Scenario II-19

Table 1: Worldwide Imaging Agents Market (2009): Percentage

Breakdown of Value Sales for Leading Players- GE Healthcare,

Bracco, Covidien, Bayer Schering Pharma, and Others (includes

corresponding Graph/Chart) II-19

Table 2: X-ray Medical Contrast Media Market Worldwide(2009): Percentage Breakdown of Sales for GE Healthcare,Bracco, Covidien, Bayer Schering Pharma and Others (includescorresponding Graph/Chart) II-19

Table 3: MRI Contrast Media Market Worldwide (2009):

Percentage Breakdown of Sales for Bayer Schering Pharma, GE

Healthcare, Bracco, Covidien and Others (includes

corresponding Graph/Chart) II-19

Table 4: Radiopharmaceutical Contrast Media Market Worldwide:Percentage Share of Leading Players for 2007 - GE Healthcare,Bristol-Myers Squibb, Mallinckrodt/ Covidien, MDS Nordion andOthers (Revenue Share) (includes corresponding Graph/Chart) II-20

4. TECHNOLOGY BREAKTHROUGHS II-21

Molecular Imaging Agents: The Outer Limits II-21

On Cards: Hyperpolarized Gases as Contrast Agents II-21

Imaging Agents Make a Welcome Impact in the Field of

Alzheimer's Disease II-22

Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging II-22

A New Imaging Agent for Radiopharmaceutical Scans II-22

Multi-Modal Image Registration: Combating Contrast Medium

Inconsistencies II-22

Saline Flushes To Help Ensure Accurate Delivery of Contrast

Agents II-23

5. PRODUCT OVERVIEW II-24Contrast Agents II-24Contrast Media: How Do They Function? II-24Where Are They Used ? II-25Evolution of Contrast Media: A Profile II-25Bismuth Nitrate: Beginning of Contrast Agents II-25Imaging Agents: Significant Developments in the Last Fifty Years II-26Schering Develops First Intravenous Contrast Agent II-26MRI: Creating a New Era for Contrast Agents II-26A Peek into the Finer Points of Differences Among Contrast Media II-26Viscosity II-26Osmolality II-27Chemotoxicity II-27Second Generation Non-Ionic Contrast Agents: An Introduction II-27Choice of the Contrast Medium: A Weighty Decision II-27Factors affecting choice of Imaging Agents II-27Taxonomy II-28Types of Contrast Media II-28X-Ray Contrast Medium II-28First Generation High Osmolar Contrast Media II-29Second Generation Low Osmolar Contrast Media or LOCM II-29Table 5: Comparative Analysis of Structure of Non-ionic andionic X-ray Contrast Media II-29MRI Contrast Medium II-29Role of Contrast Enhancement in MR Angiography (MRA) II-31MRI Contrast Agents for the Liver II-31Paramagnetic extracellular contrast agents II-31Hepatobiliary Gadolinium Chelates II-31Superparamagnetic Iron Oxide Particles II-31Ultrasound Contrast Medium II-31Ultrasonographic Contrast Media: What Are They? II-32Ultrasound Contrast Enhancement in Cardiology II-33Functionalities of Vascular Ultrasound Contrast Agents II-33Diagnostic Radiopharmaceuticals II-33Key Radioactive Isotopes used as DiagnosticRadiopharmaceuticals II-34A Delineate of Diagnostic Radiopharmaceuticals II-35Diagnostic Radiopharmaceuticals: A Technical Run-Through II-35Applications II-36

6. A SEGMENTAL REVIEW II-37

Contrast Media II-37

Popular Brands of Contrast Agents II-37

X-ray Contrast Media II-38

Market Scenario II-38

MRI Contrast Media II-39

Market Scenario II-39

Ultrasound Contrast Media II-39

Market Overview II-39

Competitive Scenario II-40

Diagnostic Radiopharmaceuticals II-40

Market Overview II-40

Immunoconjugates II-40

Market Overview II-40

7. TECHNOLOGY DYNAMICS II-42Proprietary Technologies Making Significant In-Roads II-42Advanced Magnetics' Proprietary Colloidal SuperparamagneticParticle Technology II-42Enzon's Single Chain Antigen-Binding Technology II-42Immunomedics' Antibody Technology II-42First Generation II-42Second Generation II-42Third Generation II-42NeoRx's "Painting the Target" Technology II-43Stage - I II-43Stage - II II-43Stage - III II-43Gas Encapsulation Technology for Ultrasound Contrast Media II-43Pharmacyclics' Texaphyrin Technology II-44Regulatory Bodies II-44Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA II-44Entry Barriers II-44Research Driven Markets II-44Highly Competitive Market II-45Economies of Scale II-45Substitutes in Agents Manufacturing II-45New X-ray Diagnostic Agents II-45Amide-based Macrocyclic Ligands - Potential MRI Agents II-45Gadolinium (III) Complexes - Potential MRI Contrast Agents II-45Metal-Containing Compounds Act As Potential Contrast Agents II-45Therapeutic Applications II-45Diagnostic Applications II-46Magnetic Gels as Potential MRI Contrast Agents II-46PFCs as Diagnostic Contrast Agents II-46

8. PRODUCT LAUNCHES II-47

GE Healthcare Receives FDA Approval for DaTscan for detecting

Dopamine Transporters II-47

Targeson Launches Targestar® P-HF II-47

GE Healthcare Announces Phase II Study Results of

Flutemetamol, the PET Imaging Agent for Brain Imaging II-47

GE Healthcare Receives FDA Approval for Cysview, An Optical

Imaging Agent for Cystoscopic Detection of Papillary Bladder

Cancer II-47

INER Develops Imaging Agents for Cerebral Blood Flow II-48

Lantheus Medical Imaging Introduces Definity Ultrasound

Contrast Imaging Agent in India II-48

Sanochemia Pharmazeutika Completes DCP Phase of MRT Imaging

Agent, to Introduce Within Major European Markets by 2011 II-48

Bayer Transfers Liver MRI Contrast Medium Resovist Injection

to I'rom Pharmaceutical II-48

GE Healthcare Re-Introduces Contrast Agent, OptisonTM II-48

Lantheus Medical Imaging Introduces ABLAVAR™ in Canada II-49

VisEn Introduces ProSense® 750 FAST and Neutrophil ElastaseTM

680 FAST II-49

Bayer Works on Development of MR Contrast Agents for Breast

Cancer Diagnosis II-49

Lantheus Medical Imaging Introduces ABLAVAR™ MRA Imaging Agent II-50

VisEn Introduces Cat B 680 FAST™ Imaging Agent II-50

VisEn Medical Introduces GastroSense 750 Fluorescence Imaging

Agent II-50

VisEn Medical Unveils VivoTag® 645 Red Fluorescent Dye II-51

VisEn Medical Launches VivoTag® 680 XL Fluorescent Dye II-51

AMAG Pharmaceuticals Unveils Superparamagnetic Iron Oxide

Nanopaticles II-51

MabCure Unveils Monoclonal Antibodies II-51

VisEn Medical Introduces ReninSense680TM FAST II-52

VisEn Medical Introduces New VivoTag® 800 and OsteoSense®

Imaging Agents II-52

VisEn Medical Introduces Annexin-Vivo 750 Imaging Agent II-52

VisEn Introduces New Fluorescence Molecular Imaging Agent,

IntegriSense™ 750 II-53

9. RECENT INDUSTRY ACTIVITY II-54Covidien to Spin Off Pharma Business II-54University of Montana Receives Patents for Two New BrainImaging Agents II-54Eli Lilly Acquires Avid Radiopharmaceuticals II-54GE Global Research Secures Multi-Year NIH Grant to DevelopNerve Imaging Agent and Imaging System II-54Agfa Healthcare Snaps Insight Agents II-55Nordion to Divest MDS Nordion S.A. II-55Sofie Biosciences Secures Funds for Research on Molecular PETImaging Agents II-55Aposense Signs Collaboration Agreement With Roche II-55University of Washington to Collaborate with Cardinal Healthfor Advancement of Molecular Imaging II-56ImaginAb Joins Hand with GE Imanet for Developmental DrugResearch II-56Cancer Targeted Technology Inks Agreement with Bayer Pharmafor Cancer PET Imaging Agent II-56Lantheus Medical Imaging Wins Global Rights for GadofosvesetTrisodium II-57Avid Radiopharmaceuticals Partners with Siemens PETNETSolutions for Production of Florbetapir F 18 II-57VisEn Expands Fluorescence Imaging Intellectual PatentPortfolio through Acquisition of Bayer Schering's Portfolio II-57Cardinal Health Enters into Partnership with ProVision forCyclotrons II-57Center for Diagnostic Imaging Sets up New Imaging Center II-57ImaginAb Signs Sub Licensing Agreement for huJ591 with BZLBiologics II-58Lantheus Medical Imaging and NTP Radioisotopes Sign Agreementfor Molybdenum-99 II-58Lantheus Medical Imaging Purchases MS-325 Related Rights fromEPIX Pharmaceuticals II-58GE Healthcare Inks Agreement with Nycomed II-58Photocure Secures Reimbursement Approval for Hexvix in Germany II-59Agfa HealthCare to Acquire Insight Agents II-59Eckert & Ziegler Disinvests FCI Contrast Media Business II-60Guerbet Signs Distribution Agreement with Draximage for itsNuclear Medicine Product Range II-60ImaginAb Signs Sub Licensing Agreement for huJ591 with BZLBiologics II-60Lantheus Medical Imaging and NTP Radioisotopes Sign Agreementfor Molybdenum-99 II-61Lantheus Medical Imaging Purchases MS-325 Related Rights forSelect Markets from EPIX Pharmaceuticals II-61MDS Nordion, TRIUMF and University of British Columbia Enterinto Partnership II-61Alseres Pharmaceuticals Signs Agreement for Special ProtocolAssessment of Altropane II-62Pharmalucence Wins Approval from FDA for Sestamibi Kit II-62Covidien Obtains Approval from Health Canada for SestamibiInjection II-62MDS Nordion Commences Production of CardioGen-82 II-62

10. STRATEGIC CORPORATE DEVELOPMENTS IN PAST - A PERSPECTIVE BUILDER II-64

Avista Capital Partners Acquires Bristol-Myers Squibb Medical

Imaging II-64

Amerinet Awards Contract to Bayer HealthCare II-64

Bristol-Myers Squibb Medical Imaging Changes Name to Lantheus

Medical Imaging II-64

Bayer Schering Secures FDA Marketing Clearance for Primovist® II-65

Bracco-Eisai Secures Approval for Iomeron® 350 and Iomeron®

350 Syringe for Use in Dynamic Liver CT II-65

Covidien Signs Co-Marketing Deal with PETNET over Nuclear

Medicine Therapies II-66

EPIX Receives FDA Approval for Vasovist II-67

GE Global and NCI Partner to Speed-up Development of Cancer

and Heart Disease Diagnosing Nanoparticle Imaging Agents II-67

Lantheus Wins Contract from PPP II-68

Sanguine to Take over Rockland II-68

Starpharma Holdings Enters into an Agreement with Unilever II-68

GE Healthcare and Cardinal Health Enter Into a Deal II-68

Jubilant to Take Over DRAXIS II-69

MTTI and Bexion to Partner for Nanovesicle II-69

Otsuka Takes over IPP II-70

Wilex Inks Deal with IBA II-70

Eusa Pharma Takes Over Cytogen II-70

Bracco Group Acquires E-Z-EM II-70

EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)

for Vasovist II-71

Bayer Schering, FutureChem Ink Licensing Deal II-71

NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive

Imaging Agent II-71

Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals II-71

Bracco Diagnostics Inks Agreement with HealthTrust Purchasing

Group II-71

Bracco Diagnostics Offers MRI Products to HealthTrust

Purchasing Group II-71

Bayer HealthCare Offers MRI Contrast Agent to HealthTrust II-72

Bayer HealthCare Extends Contract with Premier II-72

Bayer HealthCare Sets Off US Operations II-72

Tyco Healthcare Renamed to Covidien Ltd II-72

Covidien Offers Imaging Solutions to MedAssets Supply Chain

Systems II-72

Siemens, M.D. Anderson Cancer Center Set up Research Centre II-72

Bayer, Berlex Merge Operations II-73

AION Diagnostics Forays Pre-Clinical Imaging Agent Market II-73

ART Acquires Alerion Biomedical II-73

EPIX to Merge with Predix II-73

Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories II-73

Bracco Diagnostics Inks Agreement with Amerinet II-74

Vasovist receives Green Signal in Australia II-74

AION Diagnostics Develops BioSilicon TM II-74

Sonazoid Receives Import Approval II-74

11. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVEBUILDER II-75Insight Agents to Launch Generic Contrast Media Solutions InEurope II-75Researchers Develop First Biocompatible MRI Contrast Agent II-75Signalomics and Invitrogen Collaborate to Develop NanocrystalReagents II-75Schering AG Collaborates with Stanford University to DevelopMolecular Imaging Agent II-75Schering and Avid to Develop Diagnostic Imaging Agents II-75US National Institutes of Health Develops two PET Imaging Agents II-76

12. FOCUS ON SELECT PLAYERS II-77

AMAG Pharmaceuticals, Inc. (USA) II-77

Bayer Schering Pharma AG (Germany) II-77

Bracco Group (Italy) II-77

Covidien (USA) II-78

Daiichi Sankyo Company Limited (Japan) II-78

Eisai Co Ltd. (Japan) II-79

EUSA Pharma, Inc. (UK) II-79

GE Healthcare (UK) II-79

Guerbet Group (France) II-80

Lantheus Medical Imaging (USA) II-80

13. GLOBAL MARKET PERSPECTIVE II-81Table 6: World Recent Past, Current & Future Analysis forImaging Agents by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), Middle East and LatinAmerica Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) II-81

Table 7: World Historic Review for Imaging Agents by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-82

Table 8: World 15-Year Perspective for Imaging Agents byGeographic Region- Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Middle East and Latin America Markets for Years 2003, 2011 &2017 (includes corresponding Graph/Chart) II-83

Table 9: World Recent Past, Current & Future Analysis for

Contrast Media by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-84

Table 10: World Historic Review for Contrast Media byGeographic Region - US, Canada, Japan, Europe, Asia- Pacific(excluding Japan), Middle East and Latin American MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2003 through 2008 (includes correspondingGraph/Chart) II-85

Table 11: World 15-Year Perspective for Contrast Media by

Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-86

Table 12: World Recent Past, Current & Future Analysis forContrast Media by Product Segments - X-Ray, MRI and UltrasoundMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) II-87

Table 13: World Historic Review for Contrast Media by Product

Segments - X-Ray, MRI and Ultrasound Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2003 through 2008 (includes corresponding Graph/Chart) II-88

Table 14: World 15-Year Perspective for Contrast Media byProduct Segments - Percentage Breakdown of Dollar Sales forX-Ray, MRI and Ultrasound Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) II-89

Table 15: World Recent Past, Current & Future Analysis for

X-Ray Contrast Media by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan), Middle East and Latin

America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-90

Table 16: World Historic Review for X-ray Contrast Media byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Middle East and Latin American MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2003 through 2008 (includes correspondingGraph/Chart) II-91

Table 17: World 15-Year Perspective for X-Ray Contrast Media

by Geographic Region- Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Markets for Years 2003, 2011 &

2017 (includes corresponding Graph/Chart) II-92

Table 18: World Recent Past, Current & Future Analysis for MRIContrast Media by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), Middle East and LatinAmerica Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) II-93

Table 19: World Historic Review for MRI Contrast Media by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin American Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) II-94

Table 20: World 15-Year Perspective for MRI Contrast Media byGeographic Region- Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan),Middle East and Latin America Markets for Years 2003, 2011 &2017 (includes corresponding Graph/Chart) II-95

Table 21: World Recent Past, Current & Future Analysis for

Ultrasound Contrast Media by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Middle East and

Latin America Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-96

Table 22: World Historic Review for Ultrasound Contrast Mediaby Geographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Middle East and Latin American MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2003 through 2008 (includes correspondingGraph/Chart) II-97

Table 23: World 15-Year Perspective for Ultrasound Contrast

Media by Geographic Region- Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), Middle East and Latin America Markets for Years 2003,

2011 & 2017 (includes corresponding Graph/Chart) II-98

Table 24: World Recent Past, Current & Future Analysis forDiagnostic Radiopharmaceuticals by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), MiddleEast and Latin America Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart) II-99

Table 25: World Historic Review for Diagnostic

Radiopharmaceuticals by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan), Middle East and

Latin American Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) II-100

Table 26: World 15-Year Perspective for DiagnosticRadiopharmaceuticals by Geographic Region- PercentageBreakdown of Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), Middle East and Latin AmericaMarkets for Years 2003, 2011 & 2017 (includes correspondingGraph/Chart) II-101III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Imaging Centers Feel the Heat During Recession III-1

Growth Stimulants III-2

Dynamics of Pricing III-2

Diagnostic Radiopharmaceuticals III-3

Market Scenario III-3

Availability of Isotopes: A Tough Challenge III-3

Radiopharmaceuticals to Drive Growth III-3

Competitive Analysis - Imaging Market III-4

Reimbursement Issues III-4

Medicare III-4

Magnetic Resonance Imaging III-5

Regulatory Environment III-6

Provisions Regarding Off-Label Usage of Contrast Media III-7

Contrast Media III-7

X-ray Contrast Media III-7

MRI Contrast Media III-7

Market Scenario III-7

Managed Care Vs MRI Technology Diffusion III-8

Ultrasound Contrast Media III-8

B.Market Analytics III-9

Table 27: US Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-9

Table 28: US Historic Review for Imaging Agents by ProductSegment - Contrast Media (X-ray, MRI and Ultrasound) andDiagnostic Radiopharmaceuticals Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-10

Table 29: US 15-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-11

2. CANADA III-12A.Market Analysis III-12Outlook III-12Diagnostic Equipment Market III-12LOCM Products Approved in Canada III-12B.Market Analytics III-13Table 30: Canadian Recent Past, Current & Future Analysisfor Imaging Agents by Product Segment- Contrast Media(X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) III-13

Table 31: Canadian Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-14

Table 32: Canadian 15-Year Perspective for Imaging Agents byProduct Segment - Percentage Breakdown of Dollar Sales forContrast Media (X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-15

3. JAPAN III-16

A.Market Analysis III-16

Outlook III-16

Reimbursement Issues III-16

B.Market Analytics III-17

Table 33: Japanese Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment - Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) III-17

Table 34: Japanese Historic Review for Imaging Agents byProduct Segment - Contrast Media (X-ray, MRI and Ultrasound)and Diagnostic Radiopharmaceuticals Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) III-18

Table 35: Japanese 15-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-19

4. EUROPE III-20A.Market Analysis III-20Outlook III-20Trends III-20Reimbursement III-20Outsourcing of Imaging Diagnostics III-21Distribution Structure III-21Direct Sales III-21License Agreements III-21Distribution Agreements III-21A Price Sensitive Market III-22Macro Environment III-22Germany III-22France III-22Spain & Italy III-22Scandinavia III-23B.Market Analytics III-24Table 36: European Recent Past, Current & Future Analysisfor Imaging Agents by Geographic Region - France, Germany,UK, Italy, Spain, Russia and Rest of Europe MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2009 through 2017 (includes corresponding Graph/Chart) III-24

Table 37: European Historic Review for Imaging Agents by

Geographic Region - France, Germany, UK, Italy, Spain,

Russia and Rest of Europe Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-25

Table 38: European 15-Year Perspective for Imaging Agents byGeographic Region - Percentage Breakdown of Dollar Sales forFrance, Germany, UK, Italy, Spain, Russia and Rest of EuropeMarkets for Years 2003, 2011 & 2017 (includes correspondingGraph/Chart) III-26

Table 39: European Recent Past, Current & Future Analysis

for Imaging Agents by Product Segment - Contrast Media

(X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) III-27

Table 40: European Historic Review for Imaging Agents byProduct Segment - Contrast Media (X-ray, MRI and Ultrasound)and Diagnostic Radiopharmaceuticals Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) III-28

Table 41: European 15-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-29

4a. FRANCE III-30A.Market Analysis III-30Growth Stimulants III-30B.Market Analytics III-30Table 42: French Recent Past, Current & Future Analysis forImaging Agents by Product Segment - Contrast Media (X-ray,MRI and Ultrasound) and Diagnostic RadiopharmaceuticalsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-30

Table 43: French Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-31

Table 44: French 15-Year Perspective for Imaging Agents byProduct Segment - Percentage Breakdown of Dollar Sales forContrast Media (X-ray, MRI and Ultrasound) & DiagnosticRadiopharmaceuticals Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-32

4b. GERMANY III-33

Market Analytics III-33

Table 45: German Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-33

Table 46: German Historic Review for Imaging Agents byProduct Segment - Contrast Media (X-ray, MRI and Ultrasound)and Diagnostic Radiopharmaceuticals Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) III-34

Table 47: German 15-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-35

4c. ITALY III-36Market Analytics III-36Table 48: Italian Recent Past, Current & Future Analysis forImaging Agents by Product Segment - Contrast Media (X-ray,MRI and Ultrasound) and Diagnostic RadiopharmaceuticalsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-36

Table 49: Italian Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-37

Table 50: Italian 15-Year Perspective for Imaging Agents byProduct Segment - Percentage Breakdown of Dollar Sales forContrast Media (X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-38

4d. THE UNITED KINGDOM III-39

Market Analytics III-39

Table 51: UK Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment - Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-39

Table 52: UK Historic Review for Imaging Agents by ProductSegment - Contrast Media (X-ray, MRI and Ultrasound) andDiagnostic Radiopharmaceuticals Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-40

Table 53: UK 15-Year Perspective for Imaging Agents by

Product Segment Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-41

4e. SPAIN III-42Market Analytics III-42Table 54: Spanish Recent Past, Current & Future Analysis forImaging Agents by Product Segment - Contrast Media (X-ray,MRI and Ultrasound) and Diagnostic RadiopharmaceuticalsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-42

Table 55: Spanish Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-43

Table 56: Spanish 15-Year Perspective for Imaging Agents byProduct Segment - Percentage Breakdown of Dollar Sales forContrast Media (X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-44

4f. RUSSIA III-45

Market Analytics III-45

Table 57: Russian Recent Past, Current & Future Analysis for

Imaging Agents by Product Segment -Contrast Media (X-ray,

MRI and Ultrasound) and Diagnostic Radiopharmaceuticals

Markets Independently Analyzed with Annual Sales in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-45

Table 58: Russian Historic Review for Imaging Agents byProduct Segment - Contrast Media (X-ray, MRI and Ultrasound)and Diagnostic Radiopharmaceuticals Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) III-46

Table 59: Russian 15-Year Perspective for Imaging Agents by

Product Segment - Percentage Breakdown of Dollar Sales for

Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-47

4g. REST OF EUROPE III-48Market Analytics III-48Table 60: Rest of Europe Recent Past, Current & FutureAnalysis for Imaging Agents by Product Segment - ContrastMedia (X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) III-48

Table 61: Rest of Europe Historic Review for Imaging Agents

by Product Segment - Contrast Media (X-ray, MRI and

Ultrasound) and Diagnostic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-49

Table 62: Rest of Europe 15-Year Perspective for ImagingAgents by Product Segment - Percentage Breakdown of DollarSales for Contrast Media (X-ray, MRI and Ultrasound) andDiagnostic Radiopharmaceuticals Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) III-50

5. ASIA-PACIFIC III-51

A.Market Analysis III-51

MRI Market in Asia III-51

ANSTO: Leading the Radiopharmaceuticals Market III-51

India - A High Potential Market III-51

B.Market Analytics III-52

Table 63: Asia-Pacific Recent Past, Current & Future

Analysis for Imaging Agents by Product Segment - Contrast

Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) III-52

Table 64: Asia-Pacific Historic Review for Imaging Agents byProduct Segment - Contrast Media (X-ray, MRI and Ultrasound)and Diagnostic Radiopharmaceuticals Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) III-53

Table 65: Asia-Pacific 15-Year Perspective for Imaging

Agents by Product Segment - Percentage Breakdown of Dollar

Sales for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011

& 2017 (includes corresponding Graph/Chart) III-54

6. THE MIDDLE EAST III-55Market Analytics III-55Table 66: Middle East Recent Past, Current & Future Analysisfor Imaging Agents by Product Segment - Contrast Media(X-ray, MRI and Ultrasound) and DiagnosticRadiopharmaceuticals Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) III-55

Table 67: Middle East Historic Review for Imaging Agents by

Product Segment - Contrast Media (X-ray, MRI and Ultrasound)

and Diagnostic Radiopharmaceuticals Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) III-56

Table 68: Middle East 15-Year Perspective for Imaging Agentsby Product Segment - Percentage Breakdown of Dollar Salesfor Contrast Media (X-ray, MRI and Ultrasound) andDiagnostic Radiopharmaceuticals Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) III-57

7. LATIN AMERICA III-58

A.Market Analysis III-58

Private Sector Boosts Healthcare Segment III-58

B.Market Analytics III-58

Table 69: Latin American Recent Past, Current & Future

Analysis for Imaging Agents by Product Segment - Contrast

Media (X-ray, MRI and Ultrasound) and Diagnostic

Radiopharmaceuticals Markets Independently Analyzed with

Annual Sales in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) III-58

Table 70: Latin American Historic Review for Imaging Agentsby Product Segment - Contrast Media (X-ray, MRI andUltrasound) and Diagnostic RadiopharmaceuticalsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2003 through 2008 (includes correspondingGraph/Chart) III-59

Table 71: Latin American 15-Year Perspective for Imaging

Agents by Product Segment - Percentage Breakdown of Dollar

Sales for Contrast Media (X-ray, MRI and Ultrasound) and

Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011

& 2017 (includes corresponding Graph/Chart) III-60

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 55 (including Divisions/Subsidiaries - 68)

------------------------------------------Region/Country Players------------------------------------------The United States 36 Canada 3Japan 5Europe 18France 1Germany 6The United Kingdom 3Italy 2Rest of Europe 6Asia-Pacific (Excluding Japan) 5Africa 1------------------------------------------

To order this report: Medical Imaging Industry: Global Imaging Agents Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________
Contact Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... DIEGO , Feb. 10, 2016 ALSP, Inc. ... , MD as Consultant for Medical Affairs in preparation for ... Michael Pierschbacher , PhD, CEO, stated, "We are pleased ... We look forward to working with an individual of such ... We look forward to drawing deeply on his broad experience ...
(Date:2/10/2016)... , Feb. 10, 2016 Intouch Solutions, a ... identified an industry-wide trend regarding the evolution of ... organizations to efficiently deliver compelling sales presentations via ... and another in 2015, Intouch uncovered that while ... devices and DSAs, many are not using them ...
(Date:2/10/2016)... HALLANDALE, Fla. , Feb. 9, 2016  Until ... sagging were surgery or liposuction. Thankfully, the FDA approved ... freezing them to death. Coolsculpting was originally approved in ... to the thighs and now the chin. With this ... Wellness Center can use a smaller applicator, the CoolMini, ...
Breaking Medicine Technology:
(Date:2/10/2016)... Calif. (PRWEB) , ... February 10, 2016 , ... ... Water Brand. There were three leading bottled water brand owners that topped the list ... that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , ... in the North Metro Denver area. The new dental practice focuses on comfort where ... in the most relaxing environment. , While some dental visits can create anxiety for ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other joint ... is often severe, with intense swelling and redness. It is triggered by the crystallization ... older adults are the most susceptible, according to the February 2016 issue of Harvard ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Armune ... Apifiny® across their network of laboratory service centers across the country. Launched in ... aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests ...
Breaking Medicine News(10 mins):